Assessment of Potential Drug–Drug Interactions in an Oncology Unit of a Tertiary Care Teaching Hospital

Ramya Kuzhikattu Vayalil; K Jayarama Shetty; Uday Venkat Mateti

doi:10.4103/ijmpo.ijmpo_93_17

Indian Journal of Medical and Paediatric Oncology, Table of Contents

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2018; 39(04): 436-442
DOI: 10.4103/ijmpo.ijmpo_93_17

Original Article

Assessment of Potential Drug–Drug Interactions in an Oncology Unit of a Tertiary Care Teaching Hospital

Ramya Kuzhikattu Vayalil

Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangaluru, Karnataka, India

,

K Jayarama Shetty

Department of Radiology and Oncology, K.S. Hegde Medical Academy, Justice K.S. Hegde Charitable Hospital, Nitte University, Paneer, Deralakatte, Mangaluru, Karnataka, India

,

Uday Venkat Mateti

Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Paneer, Deralakatte, Mangaluru, Karnataka, India

› Author Affiliations

Abstract

Context: Drug interactions are more common in cancer patients because they consume several medicines such as hormonal substances, anticancer drugs, and adjuvant drugs to treat comorbidities. Objectives: To assess the pattern of potential drug–drug interactions (pDDIs) in an oncology unit of a tertiary care teaching hospital. Materials and Methods: A prospective observational study was carried out for 8 months (August 2016 to March 2017). Data on drugs were collected by reviewing the patients’ medical records. The drug interactions fact software version such as Micromedex electronic database system, drugs.com interaction checker, and Medscape multidrug interaction checker tool were used to identify and analyze the pattern of pDDIs. Results: A total of 180 patients were enrolled during the study period. Among them, 152 study patients had 84.44% of pDDIs. Male predominance (64.4%) was noted over female (35.6%). According to the severity of classification of pDDIs, majority of them were moderate (63.1%) followed by major (26.1%) and minor (10.1%) interactions. The interactions that potentially cause QT interval prolongation and irregular heartbeat were the common outcomes of pDDIs. Conclusions: The incidence of pDDIs among cancer patients was 84.44%. The most common interacting drug pair in the study population was found to be dexamethasone + aprepitant [41 (26.9%)] followed by cisplatin + dexamethasone [32 (21.05%)] and other interacting pairs. To avoid harmful effects, screening of pDDIs should take place before administering the therapy.

Keywords

Antineoplastic agents - chemotherapy - drug interactions

Full Text

References

References
1 Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH. Drug-drug interactions in medical patients: Effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38: 504-13
2 Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000; 14: 17-23
3 Hines LE, Murphy JE. Potentially harmful drug-drug interactions in the elderly: A review. Am J Geriatr Pharmacother 2011; 9: 364-77
4 Scripture CD, Figg WD. Drug interactions in cancer therapy. Nat Rev Cancer 2006; 6: 546-58
5 Ekincioglu AB, Demirkan K, Keskin B, Aslantas O, Ozdemir E. Potential drug interactions and side effects in an outpatient oncology clinic: A retrospective descriptive study. Eur J Hosp Sci Pract 2014; 21: 216-21
6 Micromedex Drug Interactions. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/CS/A81150/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/EFBA47/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert. FindDrugInteractions?navitem=topInteractions&isToolPage=true. [Last accessed on 2017 Mar 18].
7 Medscape Multidrug Interaction Checker. Available from: http://www.reference.medscape.com/drug-interactionchecker. [Last accessed on 2017 Mar 18].
8 Riechelmann RP, Del Giglio A. Drug interactions in oncology: How common are they?. Ann Oncol 2009; 20: 1907-12
9 Leeuwen RW, Jansman FG, Deeman F, Piran F, Vencenten I, Rijnevld AW. et al. Drug-drug interactions in patients treated for cancer: A prospective study on clinical interventions. Ann Oncol 2010; 25: 146-64
10 Ussai S, Petelin R, Giordano A, Malinconico M, Cirillo D, Pentimalli F. et al. A pilot study on the impact of known drug-drug interactions in cancer patients. J Exp Clin Cancer Res 2015; 34: 89
11 Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007; 99: 592-600
12 Ko Y, Tan SL, Chan A, Wong YP, Yong WP, Ng RC. et al. Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: A retrospective database study. Clin Ther 2012; 34: 1696-704
13 van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM. et al. Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 2013; 108: 1071-8
14 Mouzon A, Kerger J, D’Hondt L, Spinewine A. Potential interactions with anticancer agents: A cross-sectional study. Chemotherapy 2013; 59: 85-92
15 Espino MF, Carrasco D, Salinas S. Potential drug-drug interactios in hospitalised haematological patients. Int J Clin Pharma 2016; 3: 512-620